$126.68
+0.02 (+0.02%)
SAIC News19 articles
GAO Audit Casts Doubt on DOGE Savings Claims, Contractors Rally
A GAO audit reveals over half of DOGE's reported contract savings lack proper documentation, yet federal services stocks rise as contractors report strong funded backlogs.
Leadership Shuffle at Pro Medicus Amid Valuation Debate
Pro Medicus announces new CFO amid a steep year-to-date stock decline, with analysts split on its valuation. Meanwhile, U.S. markets extend weekly losses on Middle East tensions.
Alamar Biosciences Stock Jumps 31% on Strong Consumables Growth
Alamar Biosciences (ALMR) shares soared 31% after Q2 revenue surged 82%, fueled by consumables sales that lifted gross margins and strengthened the recurring revenue outlook.
Ensysce Biosciences Stock Jumps 48% Premarket, Nasdaq Compliance Still Elusive
Ensysce Biosciences (NASDAQ:ENSC) shares jumped 48% in premarket trading, yet the stock remains 141% below the $1 minimum bid price required by Nasdaq. The compliance window begins August 11.
SELLAS Life Sciences Shares Slide 3.9% as Dilution Concerns Weigh on Valuation
SELLAS Life Sciences shares dropped 3.9% on Monday as the latest share count of 196.6 million suggests a $2.14 billion market cap, 14% above the live feed. The biotech awaits final REGAL trial data.
SELLAS Life Sciences Stock Tumbles 14% on REGAL Trial Uncertainty
SELLAS Life Sciences shares dropped 14% on Friday amid investor caution over the REGAL Phase 3 trial timeline, testing the company's $2.2 billion market cap.
Jupiter Neurosciences Stock Retreats After Securing U.S. MDMA Rights
Jupiter Neurosciences shares fell from a 67% rally after securing U.S. rights for a trial-stage MDMA drug, with the stock rising only 6.2% amid concerns over financing and dilution.
SELLAS Life Sciences Stock Jumps 12% Ahead of Key Trial Results
SELLAS Life Sciences rose 12.3% on Friday, closing at $13.19, with a market cap discrepancy of $319 million ahead of REGAL trial results.
SELLAS Life Sciences Surges 12% as Equity Value Soars $1.6B
SELLAS Life Sciences shares climbed 12.3% to $13.19, lifting estimated equity value by $1.62 billion since May. The REGAL trial's 80th event is pending.
SL Science Rockets 35% in Nasdaq Debut, Valuation Hits 1,500x 2025 Sales
SL Science (SLBT) soared 35% in its Nasdaq debut, closing at $5.99, but its $3.36B market cap versus $2.2M in revenue sparks valuation debate.
Regencell Bioscience Shares Slide 63% Below May Offering Price
Regencell Bioscience (NASDAQ:RGC) dropped 6.6% to $7.50, remaining 63.1% below its May offering price, despite a brief intraday rebound. Biotech ETFs gained.
Regencell Bioscience Surges But Still 60% Below May Offering Price
Regencell Bioscience (RGC) shares surged 31.9% on Wednesday, yet still trade 60.4% below the May direct offering price. The stark rebound underscores the volatility and fundamental challenges facing the pre-revenue biotech.
SELLAS Life Sciences Soars on Heavy Short Interest Ahead of AML Trial Results
SELLAS Life Sciences (SLS) surged 6.3% to $11.19 as short interest climbed to 32.65% of float and trading volume doubled. The company amended executive severance terms and disclosed 78 of 80 events reached in its Phase 3 AML trial.
SELLAS Life Sciences Soars on Executive Severance Update
SELLAS Life Sciences (SLS) surged 12.6% to $10.33 on heavy volume after an 8-K filing revealed changes to executive severance terms. The stock's implied equity value reached $2.03 billion.
Artelo Biosciences Shares Swing Wildly After Shelf Filing
Artelo Biosciences shares plunged 10.5% to a 52-week low of $1.19 before rebounding to $2.01 in after-hours trading, driven by capital market moves and early-stage pipeline updates.
Jupiter Neurosciences Shares Plunge on $100M MDMA Deal and Dilutive Offering
Jupiter Neurosciences shares fell 37% to $0.205 after announcing a $100M licensing deal for MDMA drug ALA-002 and a $2M stock offering, with trading volume exceeding 230 million shares.
Cellectar Biosciences Secures $140M, Pushes Iopofosine Toward FDA Filing
Cellectar Biosciences secured up to $140 million in new funding and reported strong Phase 2b results for iopofosine, fueling plans for a confirmatory trial and FDA filing in Waldenström macroglobulinemia.
Sagimet Biosciences Soars After $175M Stock Sale to Fund Acne Drug Trial
Sagimet Biosciences shares surged 38% after announcing a $175 million stock offering to fund a Phase 3 acne trial for denifanstat, with proceeds expected to support dermatology programs through 2028.
Firefly Neuroscience Soars 126% on AI Brain-Scan Surge and Nvidia Partnership
Firefly Neuroscience shares surged 126% following a massive expansion in its commercial brain-scan platform and a new AI initiative powered by NVIDIA hardware. The company reported a 33-fold increase in scan volumes to over 10,800 in 2025.